1256806-33-3 Usage
Uses
Used in Pharmaceutical Drug Development:
1H-Pyrazolo[4,3-b]pyridine, 7-bromois used as a key intermediate in the synthesis of various pharmaceutical drugs. Its unique structure allows for the development of new drug candidates with potential therapeutic applications in treating different medical conditions.
Used in Organic Synthesis:
1H-Pyrazolo[4,3-b]pyridine, 7-bromoserves as a versatile building block in organic synthesis. Its reactivity and functional groups enable the formation of a wide range of chemical compounds, which can be further utilized in various applications, including the synthesis of pharmaceuticals, agrochemicals, and other specialty chemicals.
Used in Medicinal Chemistry Research:
1H-Pyrazolo[4,3-b]pyridine, 7-bromois used as a research tool in medicinal chemistry to explore its potential biological activities. Scientists and researchers investigate its interactions with biological targets, such as enzymes, receptors, and other proteins, to understand its mechanism of action and evaluate its potential as a therapeutic agent.
Used in Drug Discovery:
1H-Pyrazolo[4,3-b]pyridine, 7-bromois employed in drug discovery processes to identify novel drug candidates with potential therapeutic benefits. Its unique structure and properties make it an attractive starting point for the design and optimization of new drugs targeting various diseases and medical conditions.
Check Digit Verification of cas no
The CAS Registry Mumber 1256806-33-3 includes 10 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 7 digits, 1,2,5,6,8,0 and 6 respectively; the second part has 2 digits, 3 and 3 respectively.
Calculate Digit Verification of CAS Registry Number 1256806-33:
(9*1)+(8*2)+(7*5)+(6*6)+(5*8)+(4*0)+(3*6)+(2*3)+(1*3)=163
163 % 10 = 3
So 1256806-33-3 is a valid CAS Registry Number.
1256806-33-3Relevant articles and documents
PYRAZOLO[4,3-B]PYRIDINE-7-AMINE INHIBITORS OF ALK5
-
Page/Page column 61, (2011/12/04)
The present invention provides ALK5 inhibitors of the formula (I) wherein the variables are as defined herein. Also provided are pharmaceutical compositions, methods of making the compounds and intermediates thereof; and methods of using the compounds.